The cardiovascular safety of diabetes drugs–insights from the rosiglitazone experience
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Related articles
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SUs, in contrast, may be problematic when used in combinations because they can cause hypoglycemia and may reduce, eliminate, or minimize the weight-loss benefit of drugs such as metformin, GLP-1 RAs, and SGLT2is.993”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [993]
Citations
Cites
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Curtis, P. S., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60953-3 · Cited by 1,393
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035
Is There Clear and Convincing Evidence of Cardiovascular Risk with Rosiglitazone?
Kaul, S., & Diamond, G. A. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.65 · Cited by 8
Self-citation
Cited by
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
“Rosiglitazone is no longer available in most countries, and its prescribing remains severely restricted in the United States because of controversial findings of an increase in coronary events, although no firm association was found after an extensive review of all evidence by the FDA.((163)) In an early proof-of-conc…”
BackgroundLixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Low Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,155
“Notably the Rosiglitazone Evaluated for Cardiovascular Outcomes in oral agent combination therapy for type 2 Diabetes (RECORD) trial did not substantiate these concerns, even after readjudication of the cardiovascular events within the RECORD trial.(371) Furthermore, the PROspective pioglitAzone Clinical Trial In macr…”
Self-citationGarber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2016) · Endocrine Practice · doi:10.4158/ep151126.cs · Cited by 878
“Pioglitazone may confer CVD benefits (103,105), whereas rosiglitazone has a neutral effect on CVD risk (106,107).”
BackgroundHandelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Garber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2019-0472 · Cited by 598
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2018) · Endocrine Practice · doi:10.4158/cs-2017-0153 · Cited by 502
Fox, C. S., Golden, S. H., Anderson, C., Bray, G. A., Burke, L. E., de Boer, I. H., Deedwania, P., Eckel, R. H., Ershow, A. G., Fradkin, J., et al. (2015) · Diabetes Care · doi:10.2337/dci15-0012 · Cited by 492
“gering controversy as to whether rosiglitazonemay actually increase the risk ofMI (156,157), and this has clouded the issue concerning the potential benefits of this insulin-sensitizer drug class in atherosclerosis.”
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2017) · Endocrine Practice · doi:10.4158/ep161682.cs · Cited by 435
“Pioglitazone may confer CVD benefits (108,110), while rosiglitazone has a neutral effect on CVD risk (111,112).”
BackgroundSGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
Inzucchi, S. E., Zinman, B., Wanner, C., Ferrari, R., Fitchett, D., Hantel, S., Espadero, R.-M., Woerle, H.-J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114559852 · Cited by 399
Fox, C. S., Golden, S. H., Anderson, C., Bray, G. A., Burke, L. E., de Boer, I. H., Deedwania, P., Eckel, R. H., Ershow, A. G., Fradkin, J., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000230 · Cited by 386
Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored
McMurray, J. J. V., Gerstein, H. C., Holman, R. R., & Pfeffer, M. A. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70031-2 · Cited by 304
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2019) · Endocrine Practice · doi:10.4158/cs-2018-0535 · Cited by 297
“Pioglitazone may confer ASCVD benefits (75,76,226), while rosiglitazone has a neutral effect on ASCVD risk (227,228).”
BackgroundGliflozins in the Management of Cardiovascular Disease
Braunwald, E. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2115011 · Cited by 266
Ballestri, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i7.1724 · Cited by 262
Coronary Artery Disease and Diabetes Mellitus
Aronson, D., & Edelman, E. R. (2014) · Cardiology Clinics · doi:10.1016/j.ccl.2014.04.001 · Cited by 222
Uno, H., Wittes, J., Fu, H., Solomon, S. D., Claggett, B., Tian, L., Cai, T., Pfeffer, M. A., Evans, S. R., & Wei, L.-J. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1741 · Cited by 220
“The event rates are low in most safety studies (9, 11, 13, 14).”
Adverse effects and safety of SGLT-2 inhibitors
Halimi, S., & Vergès, B. L. (2014) · Diabetes & Metabolism · doi:10.1016/s1262-3636(14)72693-x · Cited by 170
“Controversies regarding the effects of rosiglitazone therapy on cardiovascular complications, pioglitazone on bladder cancer, and incretins on exocrine pancreatic risk, pancreatitis and pancreatic carcinoma, and even thyroid carcinoma, have raised concerns about the use of those drugs [11,13-15].”
BackgroundActis Dato, V., & Chiabrando, G. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061780 · Cited by 125
“Rosiglitazone (RGZ) is a potent PPARγ agonist with anti-diabetic properties, but it has also been associated with several cardiovascular risks [23].”
BackgroundLin, D. S.-H., Lee, J.-K., Hung, C.-S., & Chen, W.-J. (2021) · Diabetologia · doi:10.1007/s00125-021-05529-w · Cited by 108
Laiteerapong, N., Karter, A. J., Moffet, H. H., Cooper, J. M., Gibbons, R. D., Liu, J. Y., Gao, Y., & Huang, E. S. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.07.023 · Cited by 101
Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine
Mannino, G. C., Andreozzi, F., & Sesti, G. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3109 · Cited by 117
“rosiglitazone (ROSI) being suspected of bringing cardiovascular harm and retracted by the Food and Drug Administration at first, but later, it has been restored in the US market.(147) Pioglitazone (PIO) is the only TZD still marketable in Europe, and it has actually been reported to”
BackgroundReview article: the prevention and reversal of hepatic fibrosis in autoimmune hepatitis
Czaja, A. J. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12592 · Cited by 92
Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease
Lonardo, A., Ballestri, S., Targher, G., & Loria, P. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.965143 · Cited by 86
Drug safety: The concept, inception and its importance in patients’ health
Alshammari, T. M. (2014) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2014.04.008 · Cited by 90
Tao, L., Shen, S., Fu, S., Fang, H., Wang, X., Das, S., Sluijter, J. P. G., Rosenzweig, A., Zhou, Y., Kong, X., et al. (2015) · Scientific Reports · doi:10.1038/srep08374 · Cited by 84
Yiu, K., & Tse, H. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.302192 · Cited by 84
“For example, thiazolidinediones seem to provide better improvement in EPCs compared with metformin, yet they fail to demonstrate any benefit on clinical outcomes in patients with DM.(98) It is possible that existing methods used to determine EPCs are misleading.”
BackgroundGarg, V., Verma, S., & Connelly, K. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.07.005 · Cited by 82
Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review
Boyle, J. G., Livingstone, R., & Petrie, J. R. (2018) · Clinical Science · doi:10.1042/cs20171299 · Cited by 78
Modulation of Glucokinase Regulatory Protein: A Double-Edged Sword?
Brouwers, M. C. G. J., Jacobs, C., Bast, A., Stehouwer, C. D. A., & Schaper, N. C. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.08.004 · Cited by 90
“For this reason the FDA now requires that preand post-approval studies for all new antidiabetic drugs first exclude excess cardiovascular risk [62].”
BackgroundDong, Y., Lv, Q., Li, S., Wu, Y., Li, L., Li, J., Zhang, F., Sun, X., & Tong, N. (2017) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2016.11.009 · Cited by 71
AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases
Lu, Q., Li, X., Liu, J., Sun, X., Rousselle, T., Ren, D., Tong, N., & Li, J. (2019) · Bioscience Reports · doi:10.1042/bsr20181995 · Cited by 69
Coronary Artery Disease and Diabetes Mellitus
Aronson, D., & Edelman, E. R. (2015) · Heart Failure Clinics · doi:10.1016/j.hfc.2015.08.010 · Cited by 74
Vascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance
Pujadas, G., & Drucker, D. J. (2016) · Endocrine Reviews · doi:10.1210/er.2016-1078 · Cited by 65
“566 Pujadas and Drucker Vascular Biology of Proglucagon-Derived Peptides Endocrine Reviews, December 2016, 37(6):554–583”
BackgroundMethodInfluentialMolecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA
Khat, D. Z., & Husain, M. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1011-7 · Cited by 66
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
Smith, R. J., Goldfine, A. B., & Hiatt, W. R. (2016) · Diabetes Care · doi:10.2337/dc15-2237 · Cited by 60
“from the rosiglitazone cardiovascular outcome trial, which demonstrated that there was no imbalance in MACE events despite earlier doubts raised from metaanalyses of the phase 2 trial data (2).”
BackgroundSelf-citationCardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes
Xu, J., & Rajaratnam, R. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0499-5 · Cited by 59
“In 2007, the highly publicized controversy surrounding the cardiovascular safety of rosiglitazone reinforced a growing awareness that glycemic efficacy is no longer the sole determinant of anti-diabetic drug pre-approval trials [6].”
BackgroundInfluentialLiu, D., Jin, B., Chen, W., & Yun, P. (2019) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-019-0293-y · Cited by 56
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., Davidson, M., EINHORN, D. F., Garber, J. R., et al. (2015) · Endocrine Practice · doi:10.4158/ep151063.cs · Cited by 55
McNeill, B. T., Suchacki, K. J., & Stimson, R. H. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-1439 · Cited by 62
“Thiazolidinediones are peroxisome proliferator-activated receptor-γ (PPAR γ ) agonists used as insulin-sensitising drugs for the treatment of T2DM, although adverse side effects have reduced their use substantially (134).”
Where Does Metformin Stand in Modern Day Management of Type 2 Diabetes?
Ahmad, E., Sargeant, J. A., Zaccardi, F., Khunti, K., Webb, D. R., & Davies, M. J. (2020) · Pharmaceuticals · doi:10.3390/ph13120427 · Cited by 61
“In terms of TZDs, rosiglitazone was withdrawn by the FDA after it was found to be associated with adverse cardiovascular outcomes, especially HF hospitalisations and death [39,91].”
BackgroundHigh Concentrations of Rosiglitazone Reduce mRNA and Protein Levels of LRP1 in HepG2 Cells
Rondón-Ortiz, A. N., Lino Cardenas, C. L., Martínez-Málaga, J., Gonzales-Urday, A. L., Gugnani, K. S., Böhlke, M., Maher, T. J., & Pino-Figueroa, A. J. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00772 · Cited by 51
“However, RGZ has been associated with cardiovascular risks, resulting in a reconsideration of its therapeutic use (Nissen and Wolski, 2007; Hiatt et al., 2013).”
BackgroundIndole and 2,4-Thiazolidinedione conjugates as potential anticancer modulators
Corigliano, D. M., Syed, R., Messineo, S., Lupia, A., Patel, R. V., Reddy, C. V. R., Dubey, P. K., Colica, C., Amato, R., Sarro, G. D., et al. (2018) · PeerJ · doi:10.7717/peerj.5386 · Cited by 53
Sethi, N. S., Prasad, D. N., & Singh, R. K. (2019) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557519666191029102838 · Cited by 50
Wei, J., Yang, B., Wang, R., Ye, H., Wang, Y., Wang, L., & Zhang, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1007980 · Cited by 44
“Frontiers in Endocrinology 06 inhibit TNF-a-induced oxidative stress and inflammation in endothelial cells through calcium and AMPK-dependent mechanisms (26, 27), and reduce the occurrence and progression of atherosclerotic plaque formation at an early stage and enhance plaque stability (28).”
BackgroundMetformin and cardiorenal outcomes in diabetes: A reappraisal
Petrie, J. R., Rossing, P. R., & Campbell, I. W. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13984 · Cited by 49
“47 These findings were not ultimately substantiated, 48 but nevertheless highlighted a lack of oversight of CV safety within the development of new therapies for type 2 diabetes.”
Pan-PPAR Modulation Effectively Protects APP/PS1 Mice from Amyloid Deposition and Cognitive Deficits
Kummer, M. P., Schwarzenberger, R., Sayah-Jeanne, S., Dubernet, M., Walczak, R., Hum, D. W., Schwartz, S., Axt, D., & Heneka, M. T. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8743-4 · Cited by 47
“Since TZDs have recently come under scrutiny for their potential cardiovascular side effects, some of these drugs are not longer considered as possible interventional therapeutics [34].”
BackgroundMechanisms of aerobic exercise impairment in diabetes: a narrative review
Wahl, M. P., Scalzo, R. L., Regensteiner, J. G., & Reusch, J. E. B. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00181 · Cited by 44
“Rosiglitazone is no longer commonly used in diabetes treatment, due in part to concerns that it increased risk of cardiac events [a claim the FDA later disputed (55)], and thus further research with other insulin sensitizers may be warranted.”
BackgroundThe Role of Dipeptidyl Peptidase – 4 Inhibitors in Diabetic Kidney Disease
Panchapakesan, U., & Pollock, C. A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00443 · Cited by 39
Cardioprotective anti-hyperglycaemic medications: a review of clinical trials
Ahmed, H. M., Khraishah, H., & Cho, L. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx668 · Cited by 45
“15,16 This observation came in line with already existing evidence of increased mortality with intense glycaemic control in the ACCORD trial, 8 and initial reports during the development of the peroxisome proliferator-activated receptor agonist, muraglitazar.”
Balogh, D. B., Wagner, L. J., & Fekete, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097789 · Cited by 38
“Food and Drug Administration (FDA) to issue a guidance for industry in 2008, mandating requirements for demonstrating cardiovascular safety for all new anti-hyperglycemic medications in T2DM [9].”
BackgroundMolecular Mechanisms of Type 2 Diabetes-Related Heart Disease and Therapeutic Insights
Giraldo, G. C., Román-Gonzaléz, A., Cañas, F., & García, A. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104548 · Cited by 41
“Several studies are strengthening the need for an early intensive intervention in glycemic control but with interventions without increasing the risk of hypoglycemia or cardiovascular events [72].”
Key Questions for Translation of FFA Receptors: From Pharmacology to Medicines
Suckow, A. T., & Briscoe, C. P. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_45 · Cited by 40
Pladevall, M., Riera-Guardia, N., Margulis, A. V., Varas-Lorenzo, C., Calingaert, B., & Perez-Gutthann, S. (2016) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0187-5 · Cited by 34
“Evidence has led some to question rosiglitazone ’ s adverse cardio-vascular safety profile [7 – 9].”
SGLT2 inhibitors: an evidence-based update on cardiovascular implications
Forzano, I., Wilson, S. M., Lombardi, A., Jankauskas, S. S., Kansakar, U., Mone, P., Varzideh, F., & Santulli, G. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2263354 · Cited by 34
Cardiovascular Protection with Anti-hyperglycemic Agents
DEEDWANIA, P. C., & Acharya, T. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00325-9 · Cited by 33
Targeting Hepatic Fibrosis in Autoimmune Hepatitis
Montaño‐Loza, A. J., Thandassery, R. B., & Czaja, A. J. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4254-7 · Cited by 32
Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes)
Fadini, G. P., Zatti, G., Consoli, A., Bonora, E., Sesti, G., Avogaro, A., Consoli, A., Formoso, G., Antenucci, D., Grossi, G., et al. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.08.001 · Cited by 30
Poonawalla, I. B., Bowe, A., TINDAL, M., MEAH, Y. A., & Schwab, P. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108800 · Cited by 32
Cardiovascular outcome trials of the newer anti-diabetic medications
Acharya, T., & DEEDWANIA, P. C. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.08.003 · Cited by 31
Management of type 2 diabetes: consensus of diabetes organizations
Quattrocchi, E. J., Goldberg, T., & Marzella, N. (2020) · Drugs in Context · doi:10.7573/dic.212607 · Cited by 37
New Aspects of Diabetes Research and Therapeutic Development
Satin, L. S., Soleimanpour, S. A., & Walker, E. M. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000160 · Cited by 34
Yang, Y., Huang, S., Ma, Q., Li, N., Li, R., Wang, Y., & Liu, H. (2024) · Regenerative Biomaterials · doi:10.1093/rb/rbae062 · Cited by 33
“The oral administration of RGZ exists cardiovascular risks including fluid retention, heart failure and increased levels of low-density lipoprotein cholesterol, which makes it been highly restricted access by FDA since 2010 [16].”
BackgroundVaro, R., Crowley, V. M., Sitoe, A., Madrid, L., Serghides, L., Bila, R., Mucavele, H., Mayor, A. G., Bassat, Q., & Kain, K. C. (2017) · Malaria Journal · doi:10.1186/s12936-017-1858-0 · Cited by 30
“Importantly, as of June 2013, an FDA expert panel relaxed restrictions on this drug [29].”
BackgroundAdil, M., Khan, R. A., Ghosh, P., Venkata, S. K., Kandhare, A. D., & Sharma, M. (2017) · Clinical Epidemiology and Global Health · doi:10.1016/j.cegh.2017.08.002 · Cited by 31
Cardiovascular Effects of Incretin-Based Therapies
White, W. B., & Baker, W. L. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-050214-013431 · Cited by 26
Cardiovascular outcome trials for anti-diabetes medication: A holy grail of drug development?
John, M., Unnikrishnan, A., Kalra, S., & Nair, T. (2016) · Indian Heart Journal · doi:10.1016/j.ihj.2016.02.017 · Cited by 29
“is often misunderstood as trials of glycemic efficacy by both practitioners and experts.(9) With CVOT like Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR-TIMI 53), Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin (TECOS), Examination of cardiova…”
MethodLee, H. Y., Rhee, C. K., Kang, J. Y., Park, C. K., Lee, S. Y., Kwon, S. S., Kim, Y. K., & Yoon, H. K. (2015) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.31.1.89 · Cited by 26
“Since the approval of rosiglitazone as an anti-diabetic agent, concerns about increased cardiovascular risks due to the agent have been suggested [37].”
BackgroundSuh, S., Seo, G. H., Jung, C. H., Kim, M.-K., Jin, S., Hwang, Y., Lee, B., & Kim, J. H. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.3.247 · Cited by 25
“This unexpected result caused controversy and uncertainty about the use of other dipeptidyl peptidase 4 (DPP-4) inhibitors (DPP4i) [10], even though their longterm CV outcome studies are not finished or planned yet.”
BackgroundTreatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors
Tomkin, G. H. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i5.636 · Cited by 24
Cugno, C., Kizhakayil, D., Calzone, R., Rahman, S. M., Halade, G. V., & Rahman, M. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-89827-8 · Cited by 24
Carlos, S., de Irala, J., Hanley, M., & Martínez‐González, M. Á. (2014) · Journal of Epidemiology & Community Health · doi:10.1136/jech-2014-203884 · Cited by 29
Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research Consortium
Sager, P. T., Seltzer, J. H., Turner, J. R., Anderson, J. L., Hiatt, W. R., Kowey, P. R., Prochaska, J. J., Stockbridge, N., & White, W. B. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.01.007 · Cited by 24
“unrecognized CV toxicities that lead to adverse events and that are either not identified or well characterized in the standard preapproval development program.(3) Where concerns about such events have arisen, CV safety outcome studies have been performed in a variety of therapeutic areas, including arthritis and pain…”
BackgroundSelf-citationCardiorenal syndrome and diabetes: an evil pairing
Méndez, A. B., Vergara, A., Olivella, A., Azancot, M. A., Soriano-Colomé, T., & Soler, M. J. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1185707 · Cited by 25
“This approach was motivated, in part by the high prevalence of cardiovascular disease in DM, and concerns about a poor cardiovascular benefit with different antidiabetic drugs, such as rosiglitazone (52), pioglitazone, peroxisome proliferator–activated receptor (PPAR) agonist muraglitazar (53) and sulphonylureas (54).”
BackgroundStone, J., Furuya‐Kanamori, L., Barendregt, J. J., & Doi, S. A. R. (2014) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3736 · Cited by 24
Anti-Diabetic Drugs: Cure or Risk Factors for Cancer?
Laskar, J., Bhattacharjee, K., Sengupta, M., & Choudhury, Y. (2018) · Pathology & Oncology Research · doi:10.1007/s12253-018-0402-z · Cited by 23
“rosiliglitazone was banned by the US Food and Drug Administration in September 2010 because it caused high risk of myocardial infraction [27, 28].”
BackgroundCMHX008, a PPARγ partial agonist, enhances insulin sensitivity with minor influences on bone loss
Hou, Y., Cao, X., Hu, X., Li, X., Shi, X., Wang, H., Peng, C. X., Li, J., Li, J., Li, Q., et al. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.004 · Cited by 21
“A recent safety evaluation demonstrated that rosiglitazone showed no increased risk of heart attack compared to the standard T2DM medicines metformin and sulfonylurea.(6) Another critical review performed on TZDs in the treatment of T2DM considered that TZDs should appropriately continue use after evaluating the posit…”
InfluentialExploring the Cardiorenal Benefits of SGLT2i: A Comprehensive Review
Cersosimo, A., Drera, A., Adamo, M., Metra, M., & Vizzardi, E. (2024) · Kidney and Dialysis · doi:10.3390/kidneydial4040016 · Cited by 24
“In 2008, concerns about the cardiovascular safety of rosiglitazone, a widely used antidiabetic drug [49], prompted the FDA to issue guidelines requiring new or recently approved antidiabetic therapies to demonstrate that they do not significantly increase cardiovascular (CV) risk [50].”
Comparative effectiveness of oral diabetes drug combinations in reducing glycosylated hemoglobin
Flory, J., Small, D. S., Cassano, P. A., Brillon, D. J., Mushlin, A. I., & Hennessy, S. (2013) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.13.87 · Cited by 22
Pintat, S., Fenici, P., Hammar, N., Ji, L., Khunti, K., Medina, J., Tang, F., Wittbrodt, E. T., & Surmont, F. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000627 · Cited by 20
Sharing of Clinical Trial Data: Benefits, Risks, and Uniform Principles
Rosenblatt, M., JAIN, S. H., & Cahill, M. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1299 · Cited by 18
“Real and unfortunate examples of dissemination of misleading data are available: One only needs to think about the damage done in the field of vaccines or the more recent alarm raised by some medical journals on alleged adverse cardiovascular effects of rosiglitazone (7) or statins (8) that were subsequently not confi…”
BackgroundAgarwal, S., Parashar, A., & Menon, V. (2014) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-014-0070-7 · Cited by 18
A Plethora of GLP-1 Agonists: Decisions About What to Use and When
Samson, S. L., & Garber, A. J. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0823-6 · Cited by 20
Narrative review of data supporting alternate first-line therapies over metformin in type 2 diabetes
Andraos, J., Smith, S. R., Tran, A., & Pham, D. Q. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01406-6 · Cited by 20
“These findings were ultimately refuted in 2013 but the literature led to increased CV safety oversight within the development of new therapies for type 2 diabetes [21 , 22].”
BackgroundFerrari, F., Scheffel, R. S., Martins, V. M., Santos, R. D., & Stein, R. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00515-4 · Cited by 18
“Based on these findings, in 2008, the US FDA mandated that all new hypoglycemic agents should have a proven cardiovascular safety record [11].”
BackgroundRanolazine and Its Effects on Hemoglobin A 1C
Greiner, L., Hurren, K. M., & Brenner, M. J. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016631757 · Cited by 16
“Apart from metformin and empagliflozin, no antidiabetes agent has been shown to reduce macrovascular risk, and the cardiovascular safety of many antidiabetic agents has not been established.(6,8,9) Practice guidelines instead recommend control of risk factors for CVD in patients with T2DM to reduce macrovascular compl…”
Background2,4-Thiazolidinediones as PTP 1B Inhibitors: A Mini Review (2012-2018)
Verma, S. K., Yadav, Y. S., & Thareja, S. (2019) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557518666181026092029 · Cited by 15
Type 2 Diabetes Therapies: A STEPS Approach.
Steinberg, J. A., & Carlson, L. (2019) · PubMed · Cited by 21
Myotubularin-related protein 7 activates peroxisome proliferator-activated receptor-gamma
Weidner, P., Söhn, M., Schroeder, T., Helm, L., Hauber, V., Gutting, T., Betge, J., Röcken, C., Rohrbacher, F. N., Pattabiraman, V. R., et al. (2020) · Oncogenesis · doi:10.1038/s41389-020-0238-8 · Cited by 19
Insulin resistance as a predictor of polymorbidity. Pathogenetic therapy (review)
Голивец, Т. П., Likrizon, S. V., & Dubonosova, D. G. (2022) · Актуальные проблемы медицины · doi:10.52575/2687-0940-2022-45-1-5-19 · Cited by 13
Do SGLT2 inhibitors increase the risk of amputation? Make haste slowly
Vlachopoulos, C. V., Terentes-Printzios, D. G., & Tsioufis, K. P. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1022 · Cited by 14
Seshasai, S. R. K., Bennett, R. L., Petrie, J. R., Bengus, M., Ekman, S., Dixon, M., Herz, M., Buse, J. B., & Ray, K. K. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12448 · Cited by 12
“Despite the overall efficacy and safety of GLP-1 receptor agonists having been demonstrated in short-term randomized controlled trials (RCTs) [7], increased regulatory scrutiny by the US Food and Drug Administration (FDA) since March 2008 has mandated assessments of the long-term cardiovascular safety of all new treat…”
BackgroundCardiovascular Outcome Trials of the Incretin-Based Therapies: What Do We Know So Far?
Mora, P. F., & Johnson, E. L. (2016) · Endocrine Practice · doi:10.4158/ep161481.ra · Cited by 12
Qin, X., Tan, Z., Li, Q., Zhang, S., Hu, D., Wang, D., Wang, L., Zhou, B., Liao, R. J., Wu, Z., et al. (2024) · Inflammation Research · doi:10.1007/s00011-024-01929-x · Cited by 13
“Rosiglitazone (RGZ), a thiazolidinedione class insulin sensitizer, is primarily utilized in the management of type 2 diabetes mellitus [13].”
Zhou, G., Han, X., Wu, Z., Shi, Q., & Bao, X. (2019) · PeerJ · doi:10.7717/peerj.7815 · Cited by 11
Wang, S., Chen, W. J., Hsu, L., Chien, K., & Wu, C. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008959 · Cited by 11
Chen, S.-Y., Beretta, M., Olzomer, E. M., Alexopoulos, S. J., Shah, D. P., Byrne, F. L., Salamoun, J. M., Garcia, C. J., Smith, G. C., Larance, M., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166908 · Cited by 15
“Although rosiglitazone is approved as a second-line medication for glucose management in diabetes, its use in the clinic has been limited due to the side effect of weight gain [36 – 38] and a perceived increased risk of cardiovascular events, which was later refuted [39].”
BackgroundCardiovascular Effects of Incretin Therapy in Diabetes Care
Kim, J., & Samson, S. L. (2014) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2014.0035 · Cited by 11
“Because of such concerns, the Food and Drug Administration (FDA) now requires preapproval or postapproval cardiovascular studies for all new antidiabetic medications.(13) Incretins are gut-derived hormones that enhance insulin secretion in a glucose-dependent manner.”
Background
Metadata
- Authors
- Hiatt, W. R., Kaul, S., & Smith, R. J.
- Affiliations
- University of Colorado Anschutz (US)
- Cedars-Sinai Medical Center (US)
- Brown University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-03
- Volume
- 369
- Issue
- 14
- Pages
- 1285-1287
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2329117883
- Cited by
- 204
- References
- 6
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 10 · 2023: 6 · 2022: 7 · 2021: 10 · 2020: 15 · 2019: 23 · 2018: 24 · 2017: 14 · 2016: 24 · 2015: 26 · 2014: 33 · 2013: 6
- FWCI
- 23.32
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- cardiovascular safety, diabetes drugs, rosiglitazone, thiazolidinediones, cardiovascular adverse events, drug safety
- MeSH terms
- Rosiglitazone, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Europe, Humans, Hypoglycemic Agents, Myocardial Infarction, United States, United States Food and Drug Administration, Drug Approval, Thiazolidinediones, Safety-Based Drug Withdrawals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.